{"id":"NCT02675426","sponsor":"AbbVie","briefTitle":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","officialTitle":"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-17","primaryCompletion":"2017-04-21","completion":"2022-03-10","firstPosted":"2016-02-05","resultsPosted":"2019-10-07","lastUpdate":"2023-04-11"},"enrollment":661,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","Rinvoq"]}],"arms":[{"label":"Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 30 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Upadacitinib 30 mg","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":35.7,"sd":null},{"arm":"Upadacitinib 15 mg","deltaMin":63.8,"sd":null},{"arm":"Upadacitinib 30 mg","deltaMin":66.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":167,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Croatia","Czechia","Estonia","Finland","France","Germany","Greece","Hong Kong","Hungary","Ireland","Italy","Kazakhstan","Latvia","Lithuania","Mexico","New Zealand","Poland","Portugal","Puerto Rico","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["29908669","40875187","38621793","37982966","37945286","37308218","36794283","36754548","36715850","36125701","34636000","34041702","33115760","31815649","31610021"],"seeAlso":["https://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":221},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","URINARY TRACT INFECTION","BRONCHITIS","RHEUMATOID ARTHRITIS"]}}